The Quantellect read.As of Nov 19, 2026, 10 active firms cover Viridian Therapeutics Inc: 10 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $22.00 to $50.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $34.89 sits 16% above the current $30.12. The rating mix has stayed broadly stable, with Buy-side ratings easing from 12 to 10 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.75 next quarter toward $-2.13 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Buy
Strong Buy00%
Buy10100%
Neutral00%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$34.89
+15.8% upside
Average target across 9 active firms as of Nov 19, 2026 vs $30.12 current
Highest Target$50.00
Average Target$34.89
Lowest Target$22.00
Detailed analyst forecasts for VRDN
Showing 1–10 of 10 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 10 of 10 active firms rate VRDN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VRDN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.75
Range $-0.95 – $-0.53 · 4 analysts · -17% YoY
Next period, 4 analysts expect Viridian Therapeutics Inc to earn $-0.75 a share (range $-0.95 – $-0.53), versus $-0.90 a year earlier. Full-year consensus is $-3.51, growing to $-2.13 the year after.
REVENUE · NEXT QUARTER
$68.0M
Range $53.0M – $82.8M · 4 analysts · +48100% YoY
Revenue is expected to reach $68.0M (range $53.0M – $82.8M), +48100.4% year-over-year. Full-year consensus is $74.8M, rising to $312.7M next year.
Top analysts covering Viridian Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VRDN.
#1
Laura Chico
Wedbush · Rank #55
Buy
$41.00+36.1% to target
Overall win rate
46%
+ Follow
#2
Serge Belanger
Needham · Rank #129
Buy
$34.00+12.9% to target
Overall win rate
46%
+ Follow
#3
Julian Harrison
BTIG · Rank #183
Buy
$61.00+102.5% to target
Overall win rate
41%
+ Follow
#4
Douglas Tsao
HC Wainwright & Co. · Rank #312
Buy
$22.00-27.0% to target
Overall win rate
35%
+ Follow
#5
Leland Gershell
Oppenheimer · Rank #404
Buy
$36.00+19.5% to target
Overall win rate
35%
+ Follow
VRDN stock forecast FAQ
What is VRDN's average 12-month price target?+
The 9 active firms with a live target average $34.89 for Viridian Therapeutics Inc over the next 12 months, ranging from a $50.00 high to a $22.00 low, as of Nov 19, 2026.
Is VRDN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 10 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for VRDN?+
The Street-high target is $50.00 (UBS), and the Street-low is $22.00 (HC Wainwright & Co.). The average of all 9 active-firm targets is $34.89.
How many active Wall Street firms cover VRDN?+
10 active firms have a recognized rating on Viridian Therapeutics Inc as of Nov 19, 2026, and 9 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VRDN?+
Among analysts who currently cover VRDN, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $41.00 target.
What is Viridian Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.75 per share (range $-0.95 – $-0.53) across 4 analysts. Full-year EPS is projected at $-3.51, rising to $-2.13 the following year.
How much revenue is Viridian Therapeutics Inc expected to report next quarter?+
Consensus revenue is $68.0M (range $53.0M – $82.8M). Full-year revenue is projected at $74.8M, growing to $312.7M next year.
Have analysts been upgrading or downgrading VRDN lately?+
As of Nov 19, 2026, 10 of 10 active firms rate VRDN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VRDN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.